103 primary care centres across the UK took part in the PERSIST study between January 2005 and January 2006, with 1,076 women each agreeing to participate for a six-month period.
542 were prescribed a single 70mg dose of alendronate once a week and the remainder received a single monthly 150mg dose of ibandronate and were enrolled in a free patient support programme designed to complement the drug.
The monthly ibandronate group received a welcome pack providing basic information about osteoporosis and a monthly reminder call from a trained nurse one to three days before the dose was due.
The nurses also used the opportunity to confirm dosing instructions, provide further information about osteoporosis and stress the importance of adhering to the treatment regime.
835 women completed the study, leaving 440 in the monthly ibandronate group and 395 in the weekly alendronate group.
Of these, just under 57 per cent of patients receiving monthly ibandronate tablets, together with patient support, were taking the medication after six months. The persistence rate for patients on weekly alendronate tablets was 39 per cent.
“Getting patients to continue taking prescribed medication is a major problem for healthcare professionals” says lead author Dr Alun Cooper, a family doctor from the Bridge Medical Centre in Crawley, UK.
“The World Health Organization estimates that only 50 per cent of patients with chronic diseases in developing countries stick to treatment regimes. And the American Heart Association has identified failing to take medication correctly as the number one problem in treating ill health today.
According to the International Osteoporosis Foundation one in three women over 50 suffer from osteoporosis worldwide.
“Sufferers find that their bones become increasingly brittle and this increases the risk of serious factures, especially if they don’t take their medication on a regular basis” says Dr Cooper. “It’s estimated that one in two women over 50 will experience a fracture at some time because of fragile bones, so any treatment regime that improves compliance is to be welcomed.”
The women who took part in the study had an average age of 68 and more than a third had a family history of osteoporosis.
45 per cent had already suffered a fracture, with just under a third reporting one incident and a further ten per cent reporting two. Four per cent had experienced three to five factures.
“Our study clearly shows that women who were prescribed monthly doses of ibandronate, and enrolled on a patient support programme, were much more likely to continue taking their medication than those on weekly doses of alendronate” concludes Dr Cooper.
“Evidence suggests that adhering to regular treatment for osteoporosis improves bone mass density and reduces fracture rates. This, in turn, reduces the social and economic burden of this very common and debilitating chronic condition.”
Over 100 family doctors from more than 30 counties across the UK took part in the PERIST research, which was supported by Roche Products Limited.
Annette Whibley | alfa
Speed data for the brain’s navigation system
06.12.2016 | Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE)
Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
07.12.2016 | Earth Sciences
07.12.2016 | Earth Sciences
07.12.2016 | Materials Sciences